Ticker

VALNEVA Declaration of shares and voting rights March 31, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence - Bât. A, 12 ter Quai Perrache - 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: April 3, 2026 ___________________________ * Theoretical voting rights. This…

The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.

The Phase 3 VALOR trial results showed that fewer Lyme disease cases were accrued than anticipated, and the primary endpoint was not met in the first analysis.

Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease.

U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than ​70% efficacy in a late-stage trial.